Urodynamix and Laborie to Exhibit at SIU 2007

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that the
prototype URO-NIRS Bladder Monitor system will be on display at the prestigious
29th Congress of the Societe Internationale d'Urologie ("SIU") in Paris, France
from September 2-6, 2007.


Urodynamix and Laborie Medical Technologies ("Laborie") will exhibit a working
prototype of the URO-NIRS Bladder Monitor system that is fully integrated with
Laborie's Urodynamics System. The demonstrations will be held during the SIU
exhibit at the Palais de Congres de Paris (Laborie Booth M6). The URO-NIRS
Bladder Monitor system is an investigational device and is not currently
available for sale.


Urodynamix is developing the integrated URO-NIRS Bladder Monitor for
non-invasive urodynamics testing to aid in the diagnosis of patients with lower
urinary tract symptoms. In May 2007, Urodynamix entered into a worldwide
licensing agreement with Laborie to distribute URO-NIRS technology in acute care
settings (see news release dated May 17, 2007 for details).


Subject to regulatory approvals and Laborie's launch program, Urodynamix expects
the URO-NIRS Bladder Monitor system to be available for launch in the US, Europe
and Canada by the end of 2007.


About SIU 2007

The Societe Internationale d'Urologie is an international professional
organization serving the global community of urologists. Founded in Paris in
1907, the SIU Central Office now serves its members from new premises in
Montreal, Canada. SIU members represent the full spectrum of clinicians and
investigators from all subspecialties that come together to diagnose, treat and
support patients with urological disease. The Society's mission is to enable
urologists in all nations, through international cooperation in education and
research, to apply the highest standards of urological care to their patients.


About Laborie Medical Technologies

Founded in 1967 by Ray Laborie, a Canadian medical device specialist, Laborie
Medical Technologies is the leading global manufacturer of urodynamics equipment
used in the diagnosis and treatment of incontinence. Laborie's product line
consists of the industry's most advanced urodynamics, compact ultrasound imaging
and biofeedback/stimulation systems, patient management software, catheters and
disposables. In addition to utilizing the latest advances in technology, Laborie
produces and sponsors leading educational courses in urodynamics for doctors,
nurses and technicians around the world each year.


Laborie introduced the first computerized Urodynamics UDS(TM) processor in 1984,
and now claims the largest and most knowledgeable UDS sales force in the world
with offices in Ontario, Quebec, Vermont, Belgium, China and now the UK. It has
direct sales and distribution networks in 52 countries across North America,
Europe and Austral-Asia. In addition to an extensive sales force, Laborie's team
of over 30 on-staff engineers, field technicians and UDS nurses install UDS
systems, train users, and work in concert with leading clinician-researchers and
local universities. These resources ensure that Laborie can bring the talent and
technical knowledge necessary to assure that its products incorporate the most
recent advancements and also reflect the practical realities of the typical
urology or urogynecology clinic.


About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for
large and growing global healthcare markets. The Company is currently developing
medical devices that use near-infrared spectroscopy (NIRS) to aid in the
diagnosis and treatment of urological conditions, intra-abdominal hypertension
and compartment syndrome, erectile dysfunction and vascular diseases.
Urodynamix's disruptive technology has the potential to beneficially affect more
than 200 million people worldwide.


On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.